PUBLIC COMPANY
save$SNYSanofi
$SNY46.52+1.00%Paris, FRupdated 2h ago
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in the Forbes Global 2000 was 89.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval433 co-mentions · 217 sources
- company$SNYNFSanofi234 co-mentions · 225 sources
- drugRIFADIN233 co-mentions · 117 sources
- tagSmall Molecule168 co-mentions · 168 sources
- drugrifampin117 co-mentions · 117 sources
- drugRIFATER50 co-mentions · 25 sources
- drugPRIMAQUINE36 co-mentions · 18 sources
- drugrifapentine34 co-mentions · 17 sources
pipeline
27
marketed
1
phase 3
9
catalysts ytd
7
approvals ytd
1
recalls ytd
0
Pipeline(27)
view full pipeline →pipeline depth27 products
1Preclinical2Phase 112Phase 29Phase 31Marketed2pre_registration
Marketed
rilzabrutinib
Acquired (Autoimmune) Hemolytic Anemia
Tyrosine-protein kinase BTK
Phase 3Coronavirus Disease 2019 (COVID-19) vaccine
Coronavirus Disease 2019 (COVID-19)
Spike glycoprotein
Phase 3Fluzone QIV HD
Unspecified Influenza Virus Infections
Phase 3SP-0218
Yellow Fever
Phase 3VerorabVax
Rabies
Phase 3avalglucosidase alfa
Pompe Disease
Phase 3frexalimab
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3gusacitinib hydrochloride
Hand Dermatitis
Phase 3riliprubart
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3venglustat malate
Fabry Disease
Phase 2IIV-HD + rC19
Coronavirus Disease 2019 (COVID-19)
Phase 2RIV3 + rC19
Coronavirus Disease 2019 (COVID-19)
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase2A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
- phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- —A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- phase2A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- phase3A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
- —A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
- —A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
- phase4Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
🐶 Hiring Signal
next earnings Jan 28, 2027
Where Sanofi is staffing up — a leading indicator of pipeline and commercial priorities.
News
- ICE detention of Princeton scientist rattles academiaA graduate student who is a scientific researcher at Princeton was detained by ICE while traveling home after presenting at a neuroscience conference.stat · 2h ago
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 8h ago
- An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory spaceIf it came to fruition, the rumored deal between Sanofi and Insmed would likely be the year’s largest, with one analyst putting a potential value for the biotech as high as $40 billion.biospace · 9h ago
- STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and moreSanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:stat · 10h ago
- STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arriveAlterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:stat · 10h ago
- Celldex drug stumbles in eczema; Epigenetic editing startup cuts staffWall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.biopharma_dive · 11h ago
- Sanofi's Infilbray wins first approval for neurological symptoms of GaucherSanofi won FDA approval Wednesday for Infilbray, the first drug in the US to treat the neurological symptoms of a rare genetic disorder called Gaucher disease. Infilbray, also known as venglustat,…endpoints · 1d ago
- Sanofi gains FDA clearance for Gaucher disease pillThe approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.biopharma_dive · 1d ago
- Sanofi considering a deal to acquire Insmed, according to reportSanofi is looking at a deal to buy the US drugmaker Insmed, Bloomberg News reported Thursday, in what would be one of the biggest biopharma takeovers of the last several years. The Bloomberg report…endpoints · 1d ago
- Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic diseaseSanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.biospace · 1d ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that